Structure-based design of non-peptide, carbohydrazide-based cathepsin K inhibitors

被引:28
作者
Thompson, SK
Halbert, SM
DesJarlais, RL
Tomaszek, TA
Levy, MA
Tew, DG
Ijames, CF
Veber, DF
机构
[1] SmithKline Beecham Pharmaceut, Dept Med Chem, King Of Prussia, PA 19406 USA
[2] SmithKline Beecham Pharmaceut, Dept Phys & Struct Chem, King Of Prussia, PA 19406 USA
[3] SmithKline Beecham Pharmaceut, Dept Mol Recognit, King Of Prussia, PA 19406 USA
关键词
cathepsin K; inhibitor; non-peptide; carbohydrazide; structure-based design;
D O I
10.1016/S0968-0896(99)00010-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Using binding models which were based on the X-ray crystal structure of an amino acid-based active site-spanning inhibitor complexed with cathepsin K, Cbz-leucine mimics have been developed, leading ultimately to the design of a potent cathepsin K inhibitor free of amino acid components. These mimics, which consist of a-substituted biphenylacetyl groups in place of Cbz-leucine moieties, effectively mimic all aspects of the Cbz-leucine moieties which are important for inhibitor binding. The predicted directions of binding for the inhibitors were confirmed by mass spectral analysis of their complexes with cathepsin K, which gave results consistent with acylation of the enzyme and loss of the acylhydrazine portion of the inhibitor which binds on the S' side of the active site. The binding models were found to be very predictive of relative inhibitor potency as well as direction of inhibitor binding. These results strengthen the validity of a strategy involving iterative cycles of structure-based design and inhibitor synthesis and evaluation for the discovery of non-peptide inhibitors. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:599 / 605
页数:7
相关论文
共 13 条
[1]   Proteolytic activity of human osteoclast cathepsin K - Expression, purification, activation, and substrate identification [J].
Bossard, MJ ;
Tomaszek, TA ;
Thompson, SK ;
Amegadzie, BY ;
Hanning, CR ;
Jones, C ;
Kurdyla, JT ;
McNulty, DE ;
Drake, FH ;
Gowen, M ;
Levy, MA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (21) :12517-12524
[2]   Use of X-ray co-crystal structures and molecular modeling to design potent and selective non-peptide inhibitors of cathepsin K [J].
DesJarlais, RL ;
Yamashita, DS ;
Oh, HJ ;
Uzinskas, IN ;
Erhard, KF ;
Allen, AC ;
Haltiwanger, RC ;
Zhao, BG ;
Smith, WW ;
Abdel-Meguid, SS ;
D'Alessio, K ;
Janson, CA ;
McQueney, MS ;
Tomaszek, TA ;
Levy, MA ;
Veber, DF .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1998, 120 (35) :9114-9115
[3]   Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts [J].
Drake, FH ;
Dodds, RA ;
James, IE ;
Connor, JR ;
Debouck, C ;
Richardson, S ;
LeeRykaczewski, E ;
Coleman, L ;
Rieman, D ;
Barthlow, R ;
Hastings, G ;
Gowen, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (21) :12511-12516
[4]  
MCKERROW JH, 1997, PERSPECT DRUG DISCOV, V6, P1
[5]   Autocatalytic activation of human cathepsin K [J].
McQueney, MS ;
Amegadzie, BY ;
DAlessio, K ;
Hanning, CR ;
McLaughlin, MM ;
McNulty, D ;
Carr, SA ;
Ijames, C ;
Kurdyla, J ;
Jones, CS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (21) :13955-13960
[6]   ON SIZE OF ACTIVE SITE IN PROTEASES .I. PAPAIN [J].
SCHECHTER, I ;
BERGER, A .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1967, 27 (02) :157-+
[7]   INHIBITORS OF HUMAN-LEUKOCYTE ELASTASE .2. SYNTHESIS AND SAR OF BENZISOTHIAZOLINYLMETHYL ARYL ETHERS [J].
SUBRAMANYAM, C ;
BELL, MR ;
FERGUSON, E ;
GORDON, RG ;
DUNLAP, RP ;
FRANKE, C ;
MURA, AJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (04) :319-324
[8]   ANTIMICROBIALS - NEW NITROFURAN DERIVATIVES [J].
SZARVASI, E ;
FONTAINE, L ;
BETBEDER.A .
JOURNAL OF MEDICINAL CHEMISTRY, 1973, 16 (03) :281-287
[9]   Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic [J].
Thompson, SK ;
Smith, WW ;
Zhao, BG ;
Halbert, SM ;
Tomaszek, TA ;
Tew, DG ;
Levy, MA ;
Janson, CA ;
D'Alessio, KJ ;
McQueney, MS ;
Kurdyla, J ;
Jones, CS ;
DesJarlais, RL ;
Abdel-Meguid, SS ;
Veber, DF .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (21) :3923-3927
[10]   Design of potent and selective human cathepsin K inhibitors that span the active site [J].
Thompson, SK ;
Halbert, SM ;
Bossard, MJ ;
Tomaszek, TA ;
Levy, MA ;
Zhao, BG ;
Smith, WW ;
Abdel-Meguid, SS ;
Janson, CA ;
D'Alessio, KJ ;
McQueney, MS ;
Amegadzie, BY ;
Hanning, CR ;
DesJarlais, RL ;
Briand, J ;
Sarkar, SK ;
Huddleston, MJ ;
Ijames, CF ;
Carr, SA ;
Garnes, KT ;
Shu, A ;
Heys, JR ;
Bradbeer, J ;
Zembryki, D ;
Lee-Rykaczewski, L ;
James, IE ;
Lark, MW ;
Drake, FH ;
Gowen, M ;
Gleason, JG ;
Veber, DF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (26) :14249-14254